You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis A randomized controlled trial
|
|---|---|
| Published in |
Annals of Allergy, Asthma & Immunology, March 2018
|
| DOI | 10.1016/j.anai.2018.03.013 |
| Pubmed ID | |
| Authors |
Tali Czarnowicki, Anders B Dohlman, Kunal Malik, Diane Antonini, Robert Bissonnette, Tom C Chan, Lisa Zhou, Huei-Chi Wen, Yeriel Estrada, Hui Xu, Catherine Bryson, Jie Shen, Deepak Lala, Avi Ma'ayan, Gerard McGeehan, Richard Gregg, Emma Guttman-Yassky |
| Abstract |
Liver X receptors (LXRs) are involved in maintaining epidermal barrier and suppressing inflammatory responses in model systems. The LXR agonist VTP-38543 showed promising results in improving barrier function and inflammatory responses in model systems. To assess the safety, tolerability, cellular and molecular changes, and clinical efficacy of the topical VTP-38543 in adults with mild to moderate atopic dermatitis (AD). A total of 104 ambulatory patients with mild to moderate AD were enrolled in this randomized, double-blind, vehicle-controlled trial between December 2015 and September 2016. VTP-38543 cream in 3 concentrations (0.05%, 0.15%, and 1.0%) or placebo was applied twice daily for 28 days. Pretreatment and posttreatment skin biopsy specimens were obtained from a subset of 33 patients. Changes in SCORing of Atopic Dermatitis, Eczema Area and Severity Index, Investigator's Global Assessment, and tissue biomarkers (by real-time polymerase chain reaction and immunostaining) were evaluated. Topical VTP-38543 was safe and well tolerated. VTP-38543 significantly increased messenger RNA (mRNA) expression of epidermal barrier differentiation (loricrin and filaggrin, P = .02) and lipid (adenosine triphosphate-binding cassette subfamily G member 1 and sterol regulatory element binding protein 1c, P < .01) measures and reduced epidermal hyperplasia markers (thickness, keratin 16 mRNA). VTP-38543 nonsignificantly suppressed cellular infiltrates and down-regulated mRNA expression of several TH17/TH22-related (phosphatidylinositol 3, S100 calcium-binding protein A12) and innate immunity (interleukin 6) markers. Topical VTP-38543 is safe and well tolerated. Its application led to improvement in barrier differentiation and lipids. Longer-term studies are needed to clarify whether a barrier-based approach can induce meaningful suppression of immune abnormalities. clinicaltrials.gov Identifier: NCT02655679. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 33% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 52 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 15% |
| Student > Master | 5 | 10% |
| Other | 3 | 6% |
| Student > Ph. D. Student | 3 | 6% |
| Student > Doctoral Student | 3 | 6% |
| Other | 8 | 15% |
| Unknown | 22 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 19% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Immunology and Microbiology | 3 | 6% |
| Chemistry | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Other | 7 | 13% |
| Unknown | 25 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2019.
All research outputs
#16,728,456
of 25,382,440 outputs
Outputs from Annals of Allergy, Asthma & Immunology
#3,020
of 4,228 outputs
Outputs of similar age
#214,133
of 348,698 outputs
Outputs of similar age from Annals of Allergy, Asthma & Immunology
#62
of 95 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,228 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.8. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,698 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.